For research use only. Not for therapeutic Use.
LRRK2 inhibitor 1 (Cat No.:I019522) is a small molecule inhibitor that targets leucine-rich repeat kinase 2 (LRRK2), an enzyme that plays a role in Parkinson’s disease. Preclinical studies have shown that this inhibitor can reduce LRRK2 activity in cells and animal models of Parkinson’s disease, making it a promising drug candidate for the treatment of this neurodegenerative disorder.
Catalog Number | I019522 |
CAS Number | 1802525-61-6 |
Molecular Formula | C₂₀H₂₃N₅O₄ |
Purity | ≥95% |
Target | LRRK2 |
Storage | Store at -20°C |
IUPAC Name | [4-[(4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino]-3-methoxyphenyl]-morpholin-4-ylmethanone |
InChI | InChI=1S/C20H23N5O4/c1-3-29-18-14-6-7-21-17(14)23-20(24-18)22-15-5-4-13(12-16(15)27-2)19(26)25-8-10-28-11-9-25/h4-7,12H,3,8-11H2,1-2H3,(H2,21,22,23,24) |
InChIKey | OTTOCUYGSZUQOI-UHFFFAOYSA-N |
SMILES | CCOC1=NC(=NC2=C1C=CN2)NC3=C(C=C(C=C3)C(=O)N4CCOCC4)OC |
Reference | [1]. Ding X, et al. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorg Med Chem Lett. 2018 May 15;28(9):1615-1620. |